1. Italy Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.

NP5.DE
Newron Pharmaceuticals S.p.A.DE flagDeutsche Börse
13.10
EUR
+0.05
- -
272.56MMarket Cap
Newron Pharmaceuticals S.p.A.
NP5.DE
(Deutsche Börse)

Recent

price

13.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.09
0.59
1.09
0.31
0.12
0.17
0.33
0.82
0.23
0.39
0.29
0.32
0.34
0.51
2.77
0.96
Revenue per Share
-3.11
-0.89
-0.29
-0.62
-0.8
-1.66
-1.04
-0.32
-0.84
-1.13
-1.18
-0.84
-0.98
-0.91
0.85
-0.66
Basic EPS, GAAP
-2.89
-0.68
0.71
-0.94
-0.79
-0.94
-1.34
-0.52
-0.9
-1.23
-0.88
-0.64
-0.62
-0.57
-0.95
1.62
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-4.18
-1.42
-0.65
-0.87
-1.13
-2.12
-1.13
-0.42
-0.93
-1.22
-1.27
-0.93
-1.08
-1
0.79
-0.71
Book Value per Share
1.06
0.19
2.01
1.04
1.76
2.69
3.37
4.15
3.07
2.06
0.97
0.17
-0.79
-1.68
0.08
-0.56
Tangible Book Value per Share
7
7
8
12
13
14
15
16
18
18
18
18
18
18
19
20
Basic Weighted Avg Shares
1
4
9
4
2
2
5
13
4
7
5
6
6
9
51
19
Sales/Revenue/Turnover
-3,456.87
-151.13
-30.22
-219.72
-720.3
-1,025.21
-318.54
-32.37
-372.12
-296.95
-343.59
-214.46
-218.28
-128.4
50.93
-24.56
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-21
-6
-2
-7
-10
-23
-15
-5
-15
-20
-21
-15
-17
-16
16
-13
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
25.95
- -
Effective Tax Rate (%)
-3,281.95
-150.27
-26.61
-200.57
-648.36
-958.66
-316.71
-39.34
-373.54
-287.11
-399.35
-258.61
-287.05
-179.13
30.83
-69.22
Profit Margin (%)
8
5
21
16
25
37
49
68
55
40
31
36
23
-9
38
-12
Working Capital
- -
2
1
1
1
- -
- -
- -
- -
17
26
43
45
26
37
1
LT Debt
12
7
28
21
29
37
50
68
55
37
17
3
-14
-30
1
-11
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
55.04
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
39.83
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-152.38%
-297.79%
-863.72%
Free Cash Flow
-15.52%
-49.59%
-283.25%
Net Income, GAAP
-27.57%
-80.02%
-183.56%
Sales/Revenue/Turnover
72.94%
93.72%
-62.78%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
9
2024
- -
- -
- -
- -
51
2025
- -
- -
- -
- -
19

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.91
2024
- -
- -
- -
- -
0.85
2025
- -
- -
- -
- -
-0.66

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Celyad Oncology S.A. (CYAD)
Sol-Gel Technologies Ltd. (SLGL)
Scopus BioPharma Inc. (SCPS)
Revolution Medicines, Inc. Warrant (RVMDW)
ABVC BioPharma, Inc. (ABVC)
Adicet Bio, Inc. (0HX7.L)
Business
Newron Pharmaceuticals S.p.A. (NWRN.SW) develops novel therapies for patients with diseases of the central nervous system and pain; its commercialized product Xadago (safinamide), a once-daily oral add-on therapy for Parkinson's disease with a unique dual mechanism of action, is marketed through partnerships including Zambon in the EU and US, and Supernus in the US; pipeline candidates include evenamide, a first-in-class add-on therapy targeting voltage-gated sodium channels for treatment-resistant schizophrenia and patients with positive symptoms inadequately controlled by antipsychotics; ralfinamide for neuropathic pain; and earlier-stage assets targeting CNS and rare diseases. The company operates primarily in Europe, with a subsidiary in Morristown, New Jersey, USA, and partners extending reach to Japan, South Korea, and Asia. Founded in 1999 and headquartered in Bresso, near Milan, Italy, Newron lists on the SIX Swiss Exchange under NWRN and on the Düsseldorf Stock Exchange under NP5.DE. Recent developments include regulatory approval for the pivotal Phase III ENIGMA-TRS program for evenamide, with enrollment initiated in ENIGMA-TRS 1 in 2025 and topline results expected in Q4 2026; licensing agreement with Myung In Pharm in January 2025 for evenamide development, production, and commercialization in South Korea, including contribution of 10% of ENIGMA-TRS 1 patients and associated costs; prior licensing deal in December 2024 with EA Pharma (Eisai subsidiary) for evenamide in Japan and select Asian countries, yielding an EUR 44 million upfront payment received in H1 2025; strengthened cash position to EUR 43.2 million at H1 2025 end, funding operations into late 2026; and ongoing pursuit of additional global partnerships for evenamide alongside new patent filings to extend intellectual property protection.